Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for P60807

Entry ID Method Resolution Chain Position Source
AF-P60807-F1 Predicted AlphaFoldDB

No variants for P60807

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for P60807

No associated diseases with P60807

3 regional properties for P60807

Type Name Position InterPro Accession
domain Histidine biosynthesis HisG, C-terminal 187 - 287 IPR013115
domain ATP phosphoribosyltransferase, catalytic domain 3 - 207 IPR013820
conserved_site ATP phosphoribosyltransferase, conserved site 145 - 166 IPR018198

Functions

Description
EC Number 2.4.2.17 Pentosyltransferases
Subcellular Localization
  • Cytoplasm
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.

3 GO annotations of molecular function

Name Definition
ATP binding Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
ATP phosphoribosyltransferase activity Catalysis of the reaction: 1-(5-phospho-D-ribosyl)-ATP + diphosphate = ATP + 5-phospho-alpha-D-ribose 1-diphosphate.
magnesium ion binding Binding to a magnesium (Mg) ion.

1 GO annotations of biological process

Name Definition
histidine biosynthetic process The chemical reactions and pathways resulting in the formation of histidine, 2-amino-3-(1H-imidazol-4-yl)propanoic acid.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MILLALPNKG RISKPVNEIL EKSGLKISVH GRSLFAKTVD PEIKVMFARA KDIPEFVRDG
70 80 90 100 110 120
VADVGVTGYD LMLERDTEEE LEMLLDFKFG NARLVLAAPE NSDVNSIEDV KNGMKIATEF
130 140 150 160 170 180
PGLTKRYLEK KGLNLEIIEL SGATEIAPFI GVSDLICDLT STGTTLQLNR LKEIENVVSS
190 200 210 220 230 240
STRLVANKKS MEDPEKSAKI NQVLSGIKSV MYAQSKRLIM MNAPKDKVSE ITSVIPGMGG
250 260 270 280
PTVSEILSNC NMLAINAVID ENKVFETVSN LEKLGARDIL VVPIERIL